Ligand Pharmaceuticals, Inc. (LGND) Tops Q1 EPS by 10c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $274.88 --0%
Revenue Growth %: +33.3%
Financial Fact:
Material sales: 4.22M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +33.3%
Financial Fact:
Material sales: 4.22M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) reported Q1 EPS of $0.35, $0.10 better than the analyst estimate of $0.25. Revenue for the quarter came in at $16 million versus the consensus estimate of $13.63 million.
For earnings history and earnings-related data on Ligand Pharmaceuticals, Inc. (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ennis (EBF) Reports In-Line Q1 EPS
- Incyte settles CMS lawsuit over Opzelura Medicaid rebate rules
- Morgan Stanley Resumes Global Payments (GPN) at Equalweight
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
